Search
Search articles by title, abstract,author or doi
Advanced search

TCR–CD3 targeting: less is more

Yiqing Wang , Junyu Xiao

Vita ››

PDF (1000KB)
Vita > Cutting Edge > DOI: 10.15302/vita.2026.06.0046
Vita Open AccessPublished:

TCR–CD3 targeting: less is more

Author information +
History +
Vita () Cite this article
PDF (1000KB)

By enforcing a strict 1:1 binding stoichiometry with the T-cell receptor, a novel anti-CD3ε antibody 4B1 uncouples TCR engagement from severe cytokine release syndrome, establishing a safer structural blueprint for next-generation T-cell engagers.

登录浏览全文

4963

注册一个新账户 忘记密码

T cells serve as the central orchestrators of adaptive immunity, broadly categorized into αβ and γδ lineages based on their T-cell receptor (TCR) composition. Conventional αβ T cells mediate antigen-specific immune responses by recognizing peptide–major histocompatibility complexes (pMHC) through the highly variable complementarity determining regions (CDRs) of the αβ heterodimer. Because the short cytoplasmic domains of the αβ chains lack intrinsic signaling capacity, signal transduction relies entirely on the non-covalently associated CD3 complex, comprising γε, δε, and ζζ dimers, which transmits activation cascades via immunoreceptor tyrosine-based activation motifs (ITAMs) embedded within their cytoplasmic tails1. Given that CD3 is uniformly and ubiquitously expressed across the entire conventional αβ T cells, therapeutic T-cell-engaging agents have almost exclusively targeted this invariant signaling module.
The evolution of anti-CD3 therapeutics beautifully illustrates how a foundational discovery can catalyze decades of rigorous mechanistic exploration. The prototype anti-CD3 monoclonal antibody, OKT3, was originally isolated as a pan-T-cell marker2, and later mapped specifically to the CD3ε subunit. OKT3 exemplifies how the CD3ε-targeted agonist can first hyper-activate, then profoundly suppress T cells. Upon binding and crosslinking TCR–CD3, OKT3 acutely leads to massive T-cell activation and cytokine release. However, this interaction simultaneously drives rapid TCR–CD3 internalization alongside the opsonization and depletion of circulating T cells. Approved by the FDA in 1986 to treat acute allograft rejection, OKT3 became the world's first therapeutic monoclonal antibody. However, its clinical utility was severely limited by the toxicities of unrestrained, multivalent cross-linking, which caused life-threatening cytokine release syndrome (CRS). Furthermore, its murine backbone induced strong immunogenicity, while its active Fc domain triggered antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)3. As its risk-benefit profile became unacceptable and other safer immunosuppressants emerged4, OKT3 usage declined, resulting in its commercial withdrawal.
The next generation of anti-CD3ε antibodies sought to resolve this dilemma through rational engineering. Teplizumab, a humanized and Fc-silencing OKT3 derivative, functions as a tolerogenic immunomodulator in delaying the onset of type 1 diabetes by mitigating immunogenicity, ADCC and CDC5. Nevertheless, teplizumab can still cause CRS, and dose monitoring and modulation remain necessary6. Thus, Fc engineering substantially blunts but does not abolish CD3-driven inflammatory side effects, highlighting an ongoing need for safer anti-CD3ε antibodies.
Concurrently, the same CD3ε handle has been repurposed for oncology via bispecific antibody (bsAb) formats. By pairing an anti-CD3 arm with a tumor-associated antigen (TAA) arm7,8, these constructs bypass pMHC restriction, pulling endogenous T cells into physical contact with tumor cells to form a synthetic, cytolytic immunological synapse. While clinically validated by agents like blinatumomab (CD3×CD19) and epcoritamab (CD3×CD20), these bsAbs remain bottlenecked by pervasive, dose-limiting CRS.
In a recent study published in Vita9, Li and colleagues characterize a novel panel of anti-CD3 monoclonal antibodies, and identify 4B1, a high-affinity clone targeting the CD3ε subunit as a leading candidate. Remarkably, despite possessing a picomolar binding affinity, higher than OKT3, 4B1 elicits drastically lower inflammatory cytokine secretion.
Using biochemical assays and cryo-electron microscopy (cryo-EM), the authors unraveled the elegant structural mechanism driving this biased activation. While the classic OKT3 Fab accommodates a 2:1 stoichiometry and binds to the CD3ε subunits of both the CD3δ/ε and CD3γ/ε heterodimers, 4B1 binds strictly in a 1:1 monovalent configuration only to the CD3ε subunit of CD3δ/ε. Structural analyses revealed that a 45° rotational shift in the binding angle of 4B1 creates a severe steric clash with the neighboring TCRβ subunit, physically obstructing it from capturing the second CD3ε chain on the same TCR complex. To further verify this physical obstruction, the authors also performed cell binding capacity and structural comparison of OKT3 and 4B1 antibodies on both αβ T cells and γδ T cells10, which intrinsically lack the TCRβ chain, the results revealed that γδ T cells exhibited the same binding capacity for both OKT3 and 4B1 antibodies, which supported the conclusion on steric constraint.
To evaluate this phenomenon in a translational context, the authors integrated the 4B1 arm into two distinct bispecific formats: IgG-scFv and CrossMab. When compared directly to OKT3-based bispecifics, the 4B1-based constructs exhibited competitive tumor cell clearing capabilities alongside substantially attenuated cytokine profiles, validating the phenotype both in cellular levels, and also within a mouse model for the CrossMab format.
Importantly, this work demonstrates that while affinity can modulate the absolute magnitude of a T-cell response, the physical valency and spatial geometry of TCR–CD3 microclustering are likely the primary drivers of hyper-inflammatory cytokine production. Because the signaling threshold required to trigger perforin and granzyme-mediated tumor lysis is lower than the high-intensity threshold required for massive IL-6 and TNF-α transcription, 4B1 likely exploits this biological window. By enforcing a strict 1:1 stoichiometry that restrains excessive microclustering, 4B1 uncouples high-affinity tumor targeting from toxic systemic inflammation, establishing a new paradigm for the design of next-generation, safer T-cell engagers.

[1]

Smith-Garvin, J.E., Koretzky, G.A. & Jordan, M.S. Annu. Rev. Immunol. 27, 591–619 (2009).

[2]

Kung, P.C., Goldstein, G., Reinherz, E.L. & Schlossman, S.F. Science 206, 347–349 (1979).

[3]

Chatenoud, L. Nat. Rev. Immunol. 3, 123–132 (2003).

[4]

Halloran, P.F. N. Engl. J. Med. 351, 2715–2729 (2004).

[5]

Herold, K.C. et al. N. Engl. J. Med. 346, 1692–1698 (2002).

[6]

Herold, K.C. et al. N. Engl. J. Med. 381, 603–613 (2019).

[7]

Bohlen, H. et al. Blood 82, 1803–1812 (1993).
[8]

Stanglmaier, M. et al. Int. J. Cancer 123, 1181–1189 (2008).

[9]

Li, X. et al. Vita https://doi.org/10.15302/vita.2026.03.0021 (2026).

[10]

Xin, W.Z. et al. Nature 630, 222–229 (2024).

RIGHTS & PERMISSIONS

The Author(s) 2026. Published by Higher Education Press. This is an Open Access article distributed under the terms of the CC BY license (https://creativecommons.org/licenses/by/4.0/).

Cite this article

Download citation ▾
Wang, Y., Xiao, J. TCR–CD3 targeting: less is more Vita https://doi.org/10.15302/vita.2026.06.0046 ()
AI Summary AI Mindmap
PDF (1000KB)
Sections
Figures
References

0

Accesses

0

Citation

Detail

Recommended

AI思维导图

/

〈 〉